1. Home
  2. INSM vs CRDO Comparison

INSM vs CRDO Comparison

Compare INSM & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • CRDO
  • Stock Information
  • Founded
  • INSM 1988
  • CRDO 2008
  • Country
  • INSM United States
  • CRDO Cayman Islands
  • Employees
  • INSM N/A
  • CRDO N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • CRDO Semiconductors
  • Sector
  • INSM Health Care
  • CRDO Technology
  • Exchange
  • INSM Nasdaq
  • CRDO Nasdaq
  • Market Cap
  • INSM 19.1B
  • CRDO 15.9B
  • IPO Year
  • INSM 2000
  • CRDO 2022
  • Fundamental
  • Price
  • INSM $103.95
  • CRDO $101.22
  • Analyst Decision
  • INSM Strong Buy
  • CRDO Strong Buy
  • Analyst Count
  • INSM 17
  • CRDO 9
  • Target Price
  • INSM $109.20
  • CRDO $86.33
  • AVG Volume (30 Days)
  • INSM 4.1M
  • CRDO 4.7M
  • Earning Date
  • INSM 08-07-2025
  • CRDO 09-03-2025
  • Dividend Yield
  • INSM N/A
  • CRDO N/A
  • EPS Growth
  • INSM N/A
  • CRDO N/A
  • EPS
  • INSM N/A
  • CRDO 0.29
  • Revenue
  • INSM $381,030,000.00
  • CRDO $436,775,000.00
  • Revenue This Year
  • INSM $28.17
  • CRDO $91.26
  • Revenue Next Year
  • INSM $120.09
  • CRDO $23.54
  • P/E Ratio
  • INSM N/A
  • CRDO $332.94
  • Revenue Growth
  • INSM 20.77
  • CRDO 126.34
  • 52 Week Low
  • INSM $60.40
  • CRDO $22.50
  • 52 Week High
  • INSM $106.83
  • CRDO $104.35
  • Technical
  • Relative Strength Index (RSI)
  • INSM 66.75
  • CRDO 64.52
  • Support Level
  • INSM $101.55
  • CRDO $88.42
  • Resistance Level
  • INSM $103.74
  • CRDO $104.35
  • Average True Range (ATR)
  • INSM 2.58
  • CRDO 5.34
  • MACD
  • INSM -0.49
  • CRDO -0.78
  • Stochastic Oscillator
  • INSM 86.11
  • CRDO 80.35

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About CRDO Credo Technology Group Holding Ltd

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

Share on Social Networks: